What is the projected market valuation of the Porcine Vaccines Market by 2035?

The Porcine Vaccines Market is projected to reach a valuation of 3.378 USD Billion by 2035. Read More

What was the market valuation of the Porcine Vaccines Market in 2024?

In 2024, the Porcine Vaccines Market was valued at 1.92 USD Billion. Read More

What is the expected CAGR for the Porcine Vaccines Market during the forecast period 2025 - 2035?

The expected CAGR for the Porcine Vaccines Market during the forecast period 2025 - 2035 is 5.27%. Read More

Which companies are considered key players in the Porcine Vaccines Market?

Key players in the Porcine Vaccines Market include Zoetis, Merck Animal Health, Boehringer Ingelheim, and Elanco Animal Health. Read More

What are the main types of vaccines in the Porcine Vaccines Market?

The main types of vaccines in the Porcine Vaccines Market include inactivated vaccines, live attenuated vaccines, toxoid vaccines, recombinant vaccines, conjugate vaccines, and DNA vaccines. Read More

What was the market size for inactivated vaccines in 2024?

In 2024, the market size for inactivated vaccines was 0.576 USD Billion. Read More

How much is the market for Porcine Reproductive & Respiratory Syndrome (PRRS) vaccines expected to grow by 2035?

The market for PRRS vaccines is expected to grow from 0.576 USD Billion in 2024 to 1.008 USD Billion by 2035. Read More

What is the projected market size for veterinary hospitals as an end-user in 2035?

The projected market size for veterinary hospitals as an end-user is expected to reach 1.68 USD Billion by 2035. Read More

What segment of the Porcine Vaccines Market is expected to see the highest growth?

The segment for live attenuated vaccines is expected to see substantial growth, increasing from 0.384 USD Billion in 2024 to 0.648 USD Billion by 2035. Read More

What is the market size for Porcine Circovirus Associated Disease (PCVAD) vaccines in 2024?

In 2024, the market size for Porcine Circovirus Associated Disease (PCVAD) vaccines was 0.384 USD Billion. Read More

Porcine Vaccines Market

ID: MRFR/Pharma/5969-HCR

90 Pages

Vikita Thakur

Last Updated: May 15, 2026

Porcine Vaccines Market Research Report Information by Type (Inactivated Vaccines, DNA Vaccines), Disease Indication (Diarrhea, Swine Influenza), End User - Forecast Till 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 Inactivated vaccines
  2. 4.1.2 Live attenuated vaccines
  3. 4.1.3 Toxoid vaccines
  4. 4.1.4 Recombinant vaccines
  5. 4.1.5 Conjugate vaccines
  6. 4.1.6 DNA vaccines
2. 4.2 Healthcare, BY Disease Indication (USD Billion)
  1. 4.2.1 PED (Porcine Epidemic Diarrhea)
  2. 4.2.2 PRRS (Porcine Reproductive & Respiratory Syndrome)
  3. 4.2.3 Swine influenza
  4. 4.2.4 Aujeszky's disease (AD)
  5. 4.2.5 Porcine Circovirus Associated Disease (PCVAD)
  6. 4.2.6 Others
3. 4.3 Healthcare, BY End-user (USD Billion)
  1. 4.3.1 Veterinary Hospitals
  2. 4.3.2 Hog Production Farm
4. 4.4 Healthcare, BY Region (USD Billion)
  1. 4.4.1 North America
    1. 4.4.1.1 US
    2. 4.4.1.2 Canada
  2. 4.4.2 Europe
    1. 4.4.2.1 Germany
    2. 4.4.2.2 UK
    3. 4.4.2.3 France
    4. 4.4.2.4 Russia
    5. 4.4.2.5 Italy
    6. 4.4.2.6 Spain
    7. 4.4.2.7 Rest of Europe
  3. 4.4.3 APAC
    1. 4.4.3.1 China
    2. 4.4.3.2 India
    3. 4.4.3.3 Japan
    4. 4.4.3.4 South Korea
    5. 4.4.3.5 Malaysia
    6. 4.4.3.6 Thailand
    7. 4.4.3.7 Indonesia
    8. 4.4.3.8 Rest of APAC
  4. 4.4.4 South America
    1. 4.4.4.1 Brazil
    2. 4.4.4.2 Mexico
    3. 4.4.4.3 Argentina
    4. 4.4.4.4 Rest of South America
  5. 4.4.5 MEA
    1. 4.4.5.1 GCC Countries
    2. 4.4.5.2 South Africa
    3. 4.4.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Zoetis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck Animal Health (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Elanco Animal Health (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ceva Santé Animale (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Vetoquinol (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Huvepharma (BG)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Phibro Animal Health (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 IDT Biologika (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY DISEASE INDICATION
5. 6.5 US MARKET ANALYSIS BY END-USER
6. 6.6 CANADA MARKET ANALYSIS BY TYPE
7. 6.7 CANADA MARKET ANALYSIS BY DISEASE INDICATION
8. 6.8 CANADA MARKET ANALYSIS BY END-USER
9. 6.9 EUROPE MARKET ANALYSIS
10. 6.10 GERMANY MARKET ANALYSIS BY TYPE
11. 6.11 GERMANY MARKET ANALYSIS BY DISEASE INDICATION
12. 6.12 GERMANY MARKET ANALYSIS BY END-USER
13. 6.13 UK MARKET ANALYSIS BY TYPE
14. 6.14 UK MARKET ANALYSIS BY DISEASE INDICATION
15. 6.15 UK MARKET ANALYSIS BY END-USER
16. 6.16 FRANCE MARKET ANALYSIS BY TYPE
17. 6.17 FRANCE MARKET ANALYSIS BY DISEASE INDICATION
18. 6.18 FRANCE MARKET ANALYSIS BY END-USER
19. 6.19 RUSSIA MARKET ANALYSIS BY TYPE
20. 6.20 RUSSIA MARKET ANALYSIS BY DISEASE INDICATION
21. 6.21 RUSSIA MARKET ANALYSIS BY END-USER
22. 6.22 ITALY MARKET ANALYSIS BY TYPE
23. 6.23 ITALY MARKET ANALYSIS BY DISEASE INDICATION
24. 6.24 ITALY MARKET ANALYSIS BY END-USER
25. 6.25 SPAIN MARKET ANALYSIS BY TYPE
26. 6.26 SPAIN MARKET ANALYSIS BY DISEASE INDICATION
27. 6.27 SPAIN MARKET ANALYSIS BY END-USER
28. 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE
29. 6.29 REST OF EUROPE MARKET ANALYSIS BY DISEASE INDICATION
30. 6.30 REST OF EUROPE MARKET ANALYSIS BY END-USER
31. 6.31 APAC MARKET ANALYSIS
32. 6.32 CHINA MARKET ANALYSIS BY TYPE
33. 6.33 CHINA MARKET ANALYSIS BY DISEASE INDICATION
34. 6.34 CHINA MARKET ANALYSIS BY END-USER
35. 6.35 INDIA MARKET ANALYSIS BY TYPE
36. 6.36 INDIA MARKET ANALYSIS BY DISEASE INDICATION
37. 6.37 INDIA MARKET ANALYSIS BY END-USER
38. 6.38 JAPAN MARKET ANALYSIS BY TYPE
39. 6.39 JAPAN MARKET ANALYSIS BY DISEASE INDICATION
40. 6.40 JAPAN MARKET ANALYSIS BY END-USER
41. 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE
42. 6.42 SOUTH KOREA MARKET ANALYSIS BY DISEASE INDICATION
43. 6.43 SOUTH KOREA MARKET ANALYSIS BY END-USER
44. 6.44 MALAYSIA MARKET ANALYSIS BY TYPE
45. 6.45 MALAYSIA MARKET ANALYSIS BY DISEASE INDICATION
46. 6.46 MALAYSIA MARKET ANALYSIS BY END-USER
47. 6.47 THAILAND MARKET ANALYSIS BY TYPE
48. 6.48 THAILAND MARKET ANALYSIS BY DISEASE INDICATION
49. 6.49 THAILAND MARKET ANALYSIS BY END-USER
50. 6.50 INDONESIA MARKET ANALYSIS BY TYPE
51. 6.51 INDONESIA MARKET ANALYSIS BY DISEASE INDICATION
52. 6.52 INDONESIA MARKET ANALYSIS BY END-USER
53. 6.53 REST OF APAC MARKET ANALYSIS BY TYPE
54. 6.54 REST OF APAC MARKET ANALYSIS BY DISEASE INDICATION
55. 6.55 REST OF APAC MARKET ANALYSIS BY END-USER
56. 6.56 SOUTH AMERICA MARKET ANALYSIS
57. 6.57 BRAZIL MARKET ANALYSIS BY TYPE
58. 6.58 BRAZIL MARKET ANALYSIS BY DISEASE INDICATION
59. 6.59 BRAZIL MARKET ANALYSIS BY END-USER
60. 6.60 MEXICO MARKET ANALYSIS BY TYPE
61. 6.61 MEXICO MARKET ANALYSIS BY DISEASE INDICATION
62. 6.62 MEXICO MARKET ANALYSIS BY END-USER
63. 6.63 ARGENTINA MARKET ANALYSIS BY TYPE
64. 6.64 ARGENTINA MARKET ANALYSIS BY DISEASE INDICATION
65. 6.65 ARGENTINA MARKET ANALYSIS BY END-USER
66. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
67. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE INDICATION
68. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
69. 6.69 MEA MARKET ANALYSIS
70. 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE
71. 6.71 GCC COUNTRIES MARKET ANALYSIS BY DISEASE INDICATION
72. 6.72 GCC COUNTRIES MARKET ANALYSIS BY END-USER
73. 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE
74. 6.74 SOUTH AFRICA MARKET ANALYSIS BY DISEASE INDICATION
75. 6.75 SOUTH AFRICA MARKET ANALYSIS BY END-USER
76. 6.76 REST OF MEA MARKET ANALYSIS BY TYPE
77. 6.77 REST OF MEA MARKET ANALYSIS BY DISEASE INDICATION
78. 6.78 REST OF MEA MARKET ANALYSIS BY END-USER
79. 6.79 KEY BUYING CRITERIA OF HEALTHCARE
80. 6.80 RESEARCH PROCESS OF MRFR
81. 6.81 DRO ANALYSIS OF HEALTHCARE
82. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
83. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
84. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
85. 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE)
86. 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
87. 6.87 HEALTHCARE, BY DISEASE INDICATION, 2024 (% SHARE)
88. 6.88 HEALTHCARE, BY DISEASE INDICATION, 2024 TO 2035 (USD Billion)
89. 6.89 HEALTHCARE, BY END-USER, 2024 (% SHARE)
90. 6.90 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
91. 6.91 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY END-USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY END-USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY END-USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY END-USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY END-USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY END-USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY END-USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY END-USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY END-USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY END-USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY END-USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY END-USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY END-USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY END-USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY END-USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY END-USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY END-USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY END-USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY END-USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY END-USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY END-USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY END-USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY END-USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY END-USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY END-USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY END-USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY END-USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DISEASE INDICATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY END-USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Inactivated vaccines
Live attenuated vaccines
Toxoid vaccines
Recombinant vaccines
Conjugate vaccines
DNA vaccines

Healthcare By Disease Indication (USD Billion, 2025-2035)

PED (Porcine Epidemic Diarrhea)
PRRS (Porcine Reproductive & Respiratory Syndrome)
Swine influenza
Aujeszky's disease (AD)
Porcine Circovirus Associated Disease (PCVAD)
Others

Healthcare By End-user (USD Billion, 2025-2035)

Veterinary Hospitals
Hog Production Farm

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”